Nicox

3:00 PM - 3:15 PM, Wednesday, June 5, 2019 ・ Theater 1
Nicox is developing innovative solutions to help maintain vision and improve ocular health. By leveraging our proprietary expertise in NO donation and other technologies, we are developing an extensive portfolio of novel product candidates that target multiple ophthalmic conditions, including glaucoma. Our portfolio includes 3programs in development including NCX 470 for intraocular pressure lowering and NCX 4251 for acute exacerbations of blepharitis. Our research activities are focused on novel future generation NO-donors including NO-donating PDE5 inhibitors and NO-donating sGC stimulators. We have 2 ophthalmology assets approved by the US FDA; VYZULTA exclusively licensed worldwide to Bausch + Lomb and commercialized in the U.S. by Bausch + Lomb since December 2017 and ZERVIATE exclusively licensed in the U.S. to Eyevance Pharmaceuticals.
Ticker:
COX
Exchange:
Euronext
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
France
Year Founded:
1996
Main Therapeutic Focus:
Lead Product in Development:
NCX 470
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
Senior Director Business Development
Nicox